Funding Momentum Pulse Therapeutics secured $10 million in financing in January 2016 led by NanoDimension, signaling investor confidence and potential for early pilots with hospital systems. This funding backdrop can help speed discussions with procurement and clinical teams at target institutions.

Magnet Clot Advantage The MED System uses magnet based technology to rapidly dissolve clots, offering a faster treatment option that could improve outcomes and reduce time to treatment for stroke and cardiovascular care. Position this as a differentiator to neurology, emergency medicine, and interventional teams.

Early Revenue Opportunity With reported revenue between one and ten million and a lean team, there is room to win early contracts through pilot programs with regional hospitals and stroke networks, supported by clinical data gathered during initial deployments.

Partnership Potential A small team and innovative technology make Pulse Therapeutics an attractive partner for larger medical device manufacturers seeking co development, licensing, or distribution agreements to scale quickly.

Go To Market Initial market focus can leverage Pulse's Missouri footprint to pilot with local academic medical centers and regional health systems, then expand to national and international markets once evidence, regulatory, and reimbursement pathways are established.